All In Biotech

Drug Trial Radar · NCT07599761

A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of ABBV-722 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

May 7, 2026

Primary completion

Sep 3, 2026

Study completion Sep 3, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.

Conditions

  • Healthy Volunteers

Interventions

  • ABBV-722Drug

    Oral Tablet

  • ItraconazoleDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
  2. Time to Cmax (Tmax) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
  3. Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
  4. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
  5. Terminal Phase Elimination Rate Constant (β) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
  6. Terminal Phase Elimination Half-Life (t1/2) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
  7. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 45 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 282143

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.